Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for […]

Hua Medicine Announces 2021 Annual Results

SHANGHAI, CHINA, Mar 17, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the “Reporting Period”). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. The New Drug […]

Hua Medicine Announces 2020 Interim Results

SHANGHAI, CHINA, Aug 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the “Reporting Period”). During the Reporting Period, the New Drug Application (NDA) of the first glucokinase activator (GKA) […]

Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine’s Dorzagliatin Readying for NDA Submission

SHANGHAI, CHINA, Mar 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the “Reporting Period”). During the Reporting Period, the Company continued to advance various clinical trials and R&D investments, […]

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial

SHANGHAI, CHINA, Dec 18, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: – Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of the COVID-19 global […]

Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin

SHANGHAI, CHINA, Oct 14, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder (“MAH”) system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau. Since the beginning […]